• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Jabil, E3D team up on auto-injector development

March 9, 2021 By Sean Whooley

Jabil HealthcareJabil (NYSE:JBL) division Jabil Healthcare announced a collaboration agreement with E3D, giving it access to E3D’s auto-injector.

The agreement with the global drug delivery device company, which is a member of the Elcam Medical Group, gives Jabil exclusive rights to develop a high-volume reusable autoinjector and connected variants, according to a news release.

St. Petersburg, Fla.-based Jabil Healthcare is now capable of developing connected auto-injectors for a range of dosing volumes and patient-centric benefits with the ultimate aim of creating a platform of these devices.

“Our collaboration with E3D enhances Jabil’s development of pharmaceutical solutions that move us into the future of connected, digital devices that are more intuitive, economical and sustainable,” Jabil Healthcare VP of pharmaceutical delivery systems James O’Gorman said in the release. “This is an exciting expansion of our relationship with E3D that will benefit our market offering and healthcare customers alike.”

“As a leader in the healthcare arena, Jabil Healthcare is the perfect partner for us and for a drug delivery market that requires the highest levels of competence, experience and scale in manufacturing,” added E3D GM Tsachi Shaked. “Our complementary expertise in electronics, manufacturing and data analysis is the type of collaboration that should help speed advances and adoption of digital health technologies.”

Filed Under: Auto-injectors, Business/Financial News, Contract Services, Drug-Device Combinations, Featured Tagged With: E3D, Jabil Healthcare

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS